Voleon Capital Management’s Ascendis Pharma A/S ASND Stock Holding History

Voleon Capital Management’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-67,839	Closed	-$15.5M	–	776
2026 Q1	$15.5M	Sell	67,839 -1,550	-2%	-$347K	0.33%	61
2025 Q4	$14.8M	Buy	69,389 +37,463	+117%	+$7.74M	0.32%	67
2025 Q3	$6.35M	Buy	+31,926	New	+$5.95M	0.16%	137

Other funds holding ASND

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Voleon Capital Management's ASND Position: Q2 2026 in Review

Voleon Capital Management sold out of Ascendis Pharma A/S (ASND) in Q2 2026, closing a stake of 67,839 shares — an estimated $15.5M sold.

Voleon Capital Management first reported a position in ASND in Q3 2025 and held it in 3 quarters. The position peaked at $15.5M in Q1 2026. 312 funds tracked by Wall St. Rank hold ASND as of Q2 2026.

Voleon Capital Management reported no remaining Ascendis Pharma A/S position as of Q2 2026 after selling out during the quarter.
Voleon Capital Management sold 67,839 Ascendis Pharma A/S shares in Q2 2026, an estimated $15.5M.
Voleon Capital Management first reported a position in Ascendis Pharma A/S in Q3 2025 and held it in 3 quarters.
Voleon Capital Management's Ascendis Pharma A/S position peaked at $15.5M in Q1 2026.
312 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q2 2026.

Based on Voleon Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.